Following joint arthroplasty, such as a hip replacement, the duration of antithrombotic therapy is a critical consideration. Aspirin, a common antiplatelet agent, is frequently prescribed to mitigate the risk of thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE). The precise period for which this medication should be administered post-operatively is determined by a variety of factors, including patient-specific risk factors and the specific surgical procedure performed.
Prophylactic use of antithrombotics is vital for preventing complications. The benefits of preventing venous thromboembolism outweigh the risks of bleeding complications in most patients undergoing hip replacement. Historical context reveals a shift towards more aggressive prophylactic strategies as understanding of venous thromboembolism pathophysiology has evolved, leading to reduced morbidity and mortality associated with these procedures.